Podcasts about Perioperative

Andy Cumpstey interviews internationally renowned anaesthetist and researcher, Kate Leslie, Head of Research in the Department of Anaesthesia and Pain Management at the Royal Melbourne Hospital and Honorary Professor at the University of Melbourne. Kate shares insights into her journey from growing up in Melbourne to leading groundbreaking research and clinical trials. We discuss her professional milestones, including her work with the Australian and New Zealand College of Anaesthetists (ANZCA) Clinical Trials Network and the global impact of their studies. Additionally, Kate reflects on the challenges and triumphs as a woman in medicine, emphasizing the importance of resilience and personal growth. The episode also highlights Kate's recent accolades, such as the ASA Excellence in Research Award and her work as an editor for major anaesthesia publications.

UROONCO BCa chief editor Dr. Benjamin Pradere (FR) talks to Prof. Christof Vulsteke (BE) on the design and results of the phase III KEYNOTE 905/EV303 study: Perioperative (periop) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible. This interview was recorded at ESMO 2025 in Berlin, Germany. For more updates on bladder cancer, please visit our educational platform UROONCO BCa.For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.

Featuring an interview with Dr Aaron Lisberg, including the following topics: Efficacy and Safety of Datopotamab Deruxtecan (Dato-DXd) for Patients with Previously Treated EGFR-Mutated Advanced Non-Small Cell Lung Cancer (NSCLC): A Pooled Analysis of the TROPION-Lung01 and TROPION-Lung05 Trials (0:00) Ahn M-J et al. Efficacy and safety of datopotamab deruxtecan (Dato-DXd) in patients (pts) with previously-treated EGFR-mutated advanced non-small cell lung cancer (NSCLC): A pooled analysis of TROPION-Lung01 and TROPION-Lung05. ESMO Asia 2024;Abstract LBA7 Ahn M-J et al. A pooled analysis of datopotamab deruxtecan in patients with EGFR-mutated NSCLC. J Thorac Oncol 2025;[Online ahead of print]. Abstract Sacituzumab Tirumotecan for Previously Treated Advanced EGFR-Mutated NSCLC: Results from the Randomized OptiTROP-Lung03 Study (7:08) Fang W et al. Sacituzumab tirumotecan versus docetaxel for previously treated EGFR-mutated advanced non-small cell lung cancer: Multicentre, open label, randomised controlled trial. BMJ 2025;389:e085680. Abstract Zhang L et al. Sacituzumab tirumotecan (sac-TMT) in patients (pts) with previously treated advanced EGFR-mutated non-small cell lung cancer (NSCLC): Results from the randomized OptiTROP-Lung03 study. ASCO 2025;Abstract 8507. Combination of Dato-DXd and Immunotherapy as First-Line Therapy for Patients with Advanced NSCLC (13:12) Cuppens K et al. First-line (1L) datopotamab deruxtecan (Dato-DXd) + durvalumab ± carboplatin in advanced or metastatic non-small cell lung cancer (a/mNSCLC): Results from TROPION-Lung04 (cohorts 2 and 4). ESMO Targeted Anticancer Therapies Congress 2025;Abstract 8O. Okamoto I et al. TROPION-Lung07: Phase III study of Dato-DXd + pembrolizumab ± platinum-based chemotherapy as 1L therapy for advanced non-small-cell lung cancer. Future Oncol 2024;20(37):2927-36. Abstract Levy BP et al. TROPION-Lung08: Phase III study of datopotamab deruxtecan plus pembrolizumab as first-line therapy for advanced NSCLC. Future Oncol 2023;19(21):1461-72. Abstract Aggarwal C et al. AVANZAR: Phase III study of datopotamab deruxtecan (Dato-DXd) + durvalumab + carboplatin as 1L treatment of advanced/mNSCLC. World Conference on Lung Cancer (WCLC) 2023;Abstract P2.04-02. TROP2-Targeting Antibody-Drug Conjugates as Neoadjuvant and/or Adjuvant Therapy for Patients with Resectable NSCLC (19:08) A phase III, randomised, open-label, global study of adjuvant datopotamab deruxtecan (Dato-DXd) in combination with rilvegostomig or rilvegostomig monotherapy versus standard of care, following complete tumour resection, in participants with Stage I adenocarcinoma non-small cell lung cancer who are ctDNA-positive or have high-risk pathological features (TROPION-Lung12). NCT06564844 Cascone T et al. Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: The platform phase 2 NeoCOAST-2 trial. Nat Med 2025;31(8):2788-96. Abstract CME information and select publications

Editor's Summary by Linda Brubaker, MD, and Preeti Malani, MD, MSJ, Deputy Editors of JAMA, the Journal of the American Medical Association, for articles published from October 11-17, 2025.

Janice Kelly, President of AORN Syntegrity (Association of periOperative Registered Nurses) joins us to explore how Artificial Intelligence is changing nursing practice. We discuss how nurses can build trust in AI, overcome integration challenges, and use technology to deliver safer, smarter patient care. Watch the video version of this episode here. AI is transforming the operating room, from pre-op planning to post-op recovery, but what does that mean for the nurses in perioperative care? AI may be the new tool, but nursing expertise remains foundational for a safe, successful surgery. You'll learn:  Why some nurses hesitate to trust AI, and how to bridge the gap Real-world examples of AI in perioperative workflows How AI supports better patient outcomes in the OR  Ethical and practical considerations for AI adoption How perioperative nurses can stay current with emerging technologies Connect with Janice on LinkedIn. Find Janice's work at: https://www.aorn.org/syntegrity Subscribe and stay at the forefront of the digital healthcare revolution. Watch the full video on YouTube @TheDigitalHealthcareExperience The Digital Healthcare Experience is a hub to connect healthcare leaders and tech enthusiasts. Powered by Taylor Healthcare, this podcast is your gateway to the latest trends and breakthroughs in digital health. Learn more at taylor.com/digital-healthcare About Us: Taylor Healthcare empowers healthcare organizations to thrive in the digital world. Our technology streamlines critical workflows such as procedural & surgical informed consent with patented mobile signature capture, ransomware downtime mitigation, patient engagement and more. For more information, please visit imedhealth.com   The Digital Healthcare Experience Podcast: Powered by Taylor Healthcare Produced by Naomi Schwimmer  Hosted by Chris Civitarese Edited by Eli Banks Music by Nicholas Bach  

Anesthesiologists (ASA), Desiree Chappell and Sol Aronson discuss the evolving economics of anesthesiology with guests Jonathon Gal, MD, Professor of Anesthesiology, Department of Anesthesiology, Perioperative and Pain Medicine, Icahn School of Medicine at Mount Sinai, System Medical Director- Facility Revenue Integrity & Optimization; System Medical Director- Offsite ASC Anesthesia; ASA Director from New York for the Board of Directors and Chair of the Committee on Economics and Gordon Morewood, MD, Anesthesiologist-in-Chief of Temple University Health System, Chair and Professor of Clinical Anesthesiology at Lewis Katz School of Medicine at Temple University and Chief of Anesthesia at Piedmont Health (Piedmont Healthcare System, Georgia). The conversation spans various models of payment, including CPT codes, fee-for-service, and alternative payment models. They delve into the nuances of navigating different payer systems like Medicare, Medicaid, and private insurers, highlighting recent trends and challenges. Specific topics include the erosion of physician payments, the impact of the No Surprises Act, and the ASA's ongoing advocacy efforts. The episode underscores the importance of proper economic strategies to ensure the sustainability and optimization of anesthesiology practices.

---------Find us atInstagram: https://www.instagram.com/abcsofanaesthesia/Twitter: https://twitter.com/abcsofaWebsite: http://www.anaesthesiacollective.comPodcast: ABCs of AnaesthesiaPrimary Exam Podcast: Anaesthesia Coffee BreakFacebook Page: https://www.facebook.com/ABCsofAnaesthesiaFacebook Private Group: https://www.facebook.com/groups/2082807131964430---------Check out all of our online courses and zoom teaching sessions here!https://anaesthesia.thinkific.com/collectionshttps://www.anaesthesiacollective.com/courses/---------#Anesthesiology #Anesthesia #Anaesthetics #Anaesthetists #Residency #MedicalSchool #FOAMed #Nurse #Medical #Meded ---------Please support me at my patreonhttps://www.patreon.com/ABCsofA---------Any questions please email abcsofanaesthesia@gmail.com---------Disclaimer: The information contained in this video/audio/graphic is for medical practitioner education only. It is not and will not be relevant for the general public.Where applicable patients have given written informed consent to the use of their images in video/photography and aware that it will be published online and visible by medical practitioners and the general public.This contains general information about medical conditions and treatments. The information is not advice and should not be treated as such. The medical information is provided “as is” without any representations or warranties, express or implied. The presenter makes no representations or warranties in relation to the medical information on this video. You must not rely on the information as an alternative to assessing and managing your patient with your treating team and consultant. You should seek your own advice from your medical practitioner in relation to any of the topics discussed in this episode' Medical information can change rapidly, and the author/s make all reasonable attempts to provide accurate information at the time of filming. There is no guarantee that the information will be accurate at the time of viewingThe information provided is within the scope of a specialist anaesthetist (FANZCA) working in Australia.The information presented here does not represent the views of any hospital or ANZCA.These videos are solely for training and education of medical practitioners, and are not an advertisement. They were not sponsored and offer no discounts, gifts or other inducements. This disclaimer was created based on a Contractology template available at http://www.contractology.com.

At this year's Evidence Based Perioperative Medicine (EBPOM) World Congress we sat down with Ramani Moonesinghe OBE, and had a conversation about her remarkable journey from her immigrant roots to her influential roles in perioperative and critical care. Hear about her contributions to Britain's National Health Service, her groundbreaking research, and her personal life balancing a demanding career with family. Gain insights into the future of perioperative care, health inequalities, and her thoughts on the nation's COVID-19 preparedness. Presented by Andy Cumpstey with Ramani Moonesinghe OBE, Professor of Perioperative Medicine, UCL, and Honorary Consultant in Anaesthesia and Perioperative Medicine, UCLH, London, UK.

Are you aware that programmed cell death-ligand 1 (PD-L1) testing may not be needed to guide immunotherapy decisions in resectable gastric/gastroesophageal junction (GEJ) cancers?   Credit available for this activity expires: 9/22/2026 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1002919?ecd=bdc_podcast_libsyn_mscpedu

In this episode, Dio Sumagaysay, Vice President of Perioperative and Multi-Specialty Procedural Services at Oregon Health & Science University, shares how his team is using iQueue for Operating Rooms' Staff Planner tool by LeanTaaS to streamline staffing across 54 operating rooms and procedural areas. He highlights the time savings, efficiency gains, and improvements in staff morale achieved through data-driven scheduling.This episode is sponsored by LeanTaaS.

LCC in Mandarin: Neoadjuvant and Perioperative Therapy for Locally Advanced NSCLC by IASLC

CME credits: 0.25 Valid until: 29-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/global-perspectives-on-perioperative-immunotherapy-in-la-hnscc/36261/ Join our experts as they examine the integration of perioperative immune checkpoint inhibitors (ICIs) in the management of resectable locally advanced head and neck squamous cell carcinoma (LA HNSCC). Drs. Le Tourneau and Harrington discuss unmet needs and limitations of current treatment and review data from trials supporting the use of perioperative ICIs, emphasizing their event-free survival and pathologic response outcomes. The conversation also addresses multidisciplinary coordination and considerations for managing immune-related adverse events. Variations in treatment guidelines, access, and clinical practice between the US, Europe, and other regions are explored to contextualize the challenges of global implementation and provide strategies for practitioners to improve care. =

Perioperative Profiles is a new series from TopMedTalk which looks at both the professional and personal journey taken by some of the world's most innovative and successful perioperative practitioners and researchers. In this, the first of the series, Andy Cumpstey interviews Professor Paul Myles, Director of Research in the Department of Anaesthesiology and Perioperative Medicine at the Alfred Hospital in Melbourne, and Head of Department at Monash University, Australia. Recorded during the Evidence Based Perioperative Medicine (EBPOM) World Congress in London this year, hear how Paul was inspired by his mother with ambitions to become a country GP and then took a trip to the United Kingdom where he was inspired by a new vision; anesthesiologists leading practice changing research. Paul Myles discusses his early years, his initial medical training at Monash University, and the pivotal experience in the UK that steered him towards anesthesiology. Hear about his transition into research, the challenges he faced, and his significant contributions, including the establishment of multi-center trials and the ANZCA Clinical Trials Network. The discussion also touches on the balance between career and family, and the future of clinical trials with adaptive designs. The episode underscores the importance of collaboration, mentorship, and persistence in achieving success in medical research.

CME credits: 0.75 Valid until: 22-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/managing-immune-related-adverse-events-in-the-perioperative-setting/36635/ This online CME activity examines advances in managing resectable locally advanced head and neck squamous cell carcinoma (HNSCC), focusing on the integration of perioperative immune checkpoint inhibitors (ICIs) and multimodal approaches. Faculty review current standards of care and highlight unmet needs that have driven investigation into combining radiation and immunotherapy. Emerging clinical trial data are discussed, including the impact of perioperative ICIs on event-free survival and pathologic response, with attention to patient selection informed by risk stratification and biomarkers. The program also addresses practical considerations for multidisciplinary care, including immune-related adverse event management and strategies to support patient access to these evolving treatment paradigms.

CME credits: 0.75 Valid until: 22-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/applying-perioperative-icis-in-clinical-practice/36634/ This online CME activity examines advances in managing resectable locally advanced head and neck squamous cell carcinoma (HNSCC), focusing on the integration of perioperative immune checkpoint inhibitors (ICIs) and multimodal approaches. Faculty review current standards of care and highlight unmet needs that have driven investigation into combining radiation and immunotherapy. Emerging clinical trial data are discussed, including the impact of perioperative ICIs on event-free survival and pathologic response, with attention to patient selection informed by risk stratification and biomarkers. The program also addresses practical considerations for multidisciplinary care, including immune-related adverse event management and strategies to support patient access to these evolving treatment paradigms.

CME credits: 0.25 Valid until: 22-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/resectable-head-neck-cancer-a-team-based-approach-to-perioperative-immunotherapy/35705/ Join our expert panel as they explore the evolving treatment landscape of resectable locally advanced head and neck squamous cell carcinoma. Learn how perioperative immune checkpoint inhibitors are improving event-free survival and get practical insights on applying this data to clinical care. The discussion highlights the importance of early multidisciplinary collaboration and offers perspectives on patient selection, treatment timing, and managing adverse events. Don't miss this opportunity to enhance your approach to reducing recurrence and disease progression in your patients.=

CME credits: 0.75 Valid until: 22-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/emerging-evidence-for-perioperative-icis-in-locally-advanced-hnscc/36593/ This online CME activity examines advances in managing resectable locally advanced head and neck squamous cell carcinoma (HNSCC), focusing on the integration of perioperative immune checkpoint inhibitors (ICIs) and multimodal approaches. Faculty review current standards of care and highlight unmet needs that have driven investigation into combining radiation and immunotherapy. Emerging clinical trial data are discussed, including the impact of perioperative ICIs on event-free survival and pathologic response, with attention to patient selection informed by risk stratification and biomarkers. The program also addresses practical considerations for multidisciplinary care, including immune-related adverse event management and strategies to support patient access to these evolving treatment paradigms.

CME credits: 0.75 Valid until: 22-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/risk-stratification-and-patient-selection-for-perioperative-icis/36633/ This online CME activity examines advances in managing resectable locally advanced head and neck squamous cell carcinoma (HNSCC), focusing on the integration of perioperative immune checkpoint inhibitors (ICIs) and multimodal approaches. Faculty review current standards of care and highlight unmet needs that have driven investigation into combining radiation and immunotherapy. Emerging clinical trial data are discussed, including the impact of perioperative ICIs on event-free survival and pathologic response, with attention to patient selection informed by risk stratification and biomarkers. The program also addresses practical considerations for multidisciplinary care, including immune-related adverse event management and strategies to support patient access to these evolving treatment paradigms.

What we do as a perioperative team matters. Day and night, 365 days a year, we save, heal and improve the wellbeing of our patients. In the Sterile Processing department (SPD), compliance with evidence- and consensus-based standards and guidelines, as well as government regulations, is of crucial importance to our work and patient safety. In episode 132, host Casey Czarnowski talks with international healthcare expert and renowned speaker Sharon Greene-Golden who has spent her distinguished career asking questions to better understand and improve processes. Greene-Golden describes compliance as working “in accordance with the established guidelines,” and she reviews the policies and procedures, standards and regulations SPDs need to be following. She also outlines recovery strategies for teams that are falling short of compliance and discusses the meaning of surgical conscience. “We have to be willing to evolve and change with time,” asserts Greene-Golden, which is why acquiring new knowledge and keeping up with continuing education is so essential. After all, she says, “Surgery begins and ends in SPD.” Earn CE Now

Navigating the fine line between effective pain control and minimizing harm from opioid medications remains one of anesthesiology's greatest challenges. This episode dives deep into the evolving landscape of perioperative pain management, examining how clinicians can achieve the delicate balance required for optimal patient outcomes.Dr. Paul Guillod joins us to share his perspective as both an anesthesiologist and pain management specialist, highlighting how opioid-sparing techniques create opportunities for interdisciplinary collaboration and improved surgical recovery. We examine the substantial risks of traditional opioid-based approaches: respiratory depression, delayed bowel function, delirium, and paradoxically, opioid-induced hyperalgesia.The episode showcases promising research on multimodal analgesia strategies that target multiple pain pathways simultaneously. By combining regional anesthesia techniques with medications like NSAIDs, acetaminophen, ketamine, dexmedetomidine, and newer options like suzetrigine, clinicians can dramatically reduce opioid requirements while maintaining effective pain control. Real-world implementation of these approaches through Enhanced Recovery After Surgery (ERAS) protocols has yielded impressive results: 50% reductions in in-hospital opioid use, shortened hospital stays, and improved pain scores across multiple surgical specialties.Whether you're a clinician seeking to improve your pain management approach or simply interested in understanding how anesthesia care is evolving to address the opioid crisis, this episode offers valuable insights into creating safer, more effective perioperative experiences. Subscribe to the Anesthesia Patient Safety Podcast and join us in our commitment that no one shall be harmed by anesthesia care.For show notes & transcript, visit our episode page at apsf.org: https://www.apsf.org/podcast/267-beyond-opioids-revolutionizing-perioperative-pain-control/© 2025, The Anesthesia Patient Safety Foundation

In this episode of Value-Based Care Insights, host Daniel Marino explores the evolving role of operating room (OR) nurse leaders within the perioperative service line. As perioperative services become an increasingly important strategic and financial focus for hospitals and health systems, the demand is growing for leaders who can combine clinical expertise with business and operational acumen. Joining the conversation is Cheryl Barratt, a seasoned healthcare consultant with over 30 years of experience in surgical services operations, system integration, and performance improvement. Cheryl discusses how perioperative nurse leaders, while strong clinically, frequently lack the training needed to manage the broader responsibilities of these roles. She shares practical insights into how organizations can support their development with leadership, financial, and strategic competencies that enable them to lead more effectively and drive long-term performance.

Host Dan Marino explores the evolving role of operating room (OR) nurse leaders within the perioperative service line. As perioperative services become an increasingly important strategic and financial focus for hospitals and health systems, the demand is growing for leaders who can combine clinical expertise with business and operational acumen. Joining the conversation is Cheryl Barratt, a seasoned healthcare consultant with over 30 years of experience in surgical services operations, system integration, and performance improvement. Cheryl discusses how perioperative nurse leaders, while strong clinically, frequently lack the training needed to manage the broader responsibilities of these roles. She shares practical insights into how organizations can support their development with leadership, financial, and strategic competencies that enable them to lead more effectively and drive long-term performance. To stream our Station live 24/7 visit www.HealthcareNOWRadio.com or ask your Smart Device to “….Play Healthcare NOW Radio”. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

Perioperative stroke represents a rare but potentially devastating complication of anesthesia care. While occurring in less than 1% of non-cardiac surgical patients, this complication fundamentally threatens not just patient outcomes but their very identity. As Dr. Jacob Nadler poignantly notes in our podcast, "By maintaining brain health, we're preserving the essence of who our patients are—their memories, their personality, their ability to connect with friends and family."The most significant recent development in this field comes from the 2024 joint guidelines that have dramatically shortened the recommended waiting period following stroke before elective surgery. What was once a nine-month wait has been reduced to just three months based on compelling evidence from a cohort study of 5.8 million patients showing risk stabilization after 90 days. This change has profound implications for surgical planning and patient care timelines.Anesthesia professionals must be vigilant about key risk factors including advanced age, previous stroke history, renal dysfunction, and anemia. The podcast explores critical medication management considerations, particularly regarding anticoagulation protocols, alongside specific intraoperative targets for blood pressure and hemoglobin levels. For suspected perioperative stroke, rapid multidisciplinary intervention with emergent brain imaging, possible thrombolytics, and mechanical thrombectomy may be indicated.For every anesthesia professional, this episode provides essential insights to help fulfill our commitment that no one shall be harmed by anesthesia care. Subscribe on Spotify or YouTube and share with colleagues to spread this vital safety information.For show notes & transcript, visit our episode page at apsf.org: https://www.apsf.org/podcast/266-protecting-the-brain-perioperative-stroke-prevention/© 2025, The Anesthesia Patient Safety Foundation

CME credits: 0.25 Valid until: 01-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/chairpersons-perspective-optimizing-perioperative-therapy-in-early-stage-nsclc-a-multidisciplinary-approach/34985/ Perioperative immunotherapy has evolved into a novel therapeutic strategy for early-stage, resectable NSCLC, maximizing the efficacy of immunotherapy when the primary tumor is still present with a high neoantigen burden. Perioperative immunotherapy also allows the use of preoperative pathology as a guide for postoperative care and offers a pathway to potential surgical intervention due to tumor shrinkage for those who are not initially eligible for surgery. Clarifying the rationale behind perioperative immunotherapy in this context is crucial for optimizing treatment strategies and outcomes. =

A revolution in pain management has arrived. The FDA's approval of Suzetrigine in January 2025 introduces the first non-opioid analgesic for moderate to severe pain in over twenty years. This breakthrough medication targets the voltage-gated sodium channel, NAV1.8, effectively blocking pain signals at their source before they reach the brain.What makes Suzetrigine remarkable is its precision. With over 30,000-fold selectivity for NAV1.8 channels, it delivers powerful analgesia without affecting the brain or heart, eliminating addiction risk, and minimizing side effects. Clinical trials involving over 2,100 patients demonstrated pain relief comparable to opioid-acetaminophen combinations but with a safety profile similar to placebo. For the more than 50% of surgical patients who experience moderate to severe postoperative pain, this non-addictive alternative represents a genuine breakthrough. Looking ahead, an exciting pipeline of additional NAV1.8 channel blockers, including intravenous formulations, promises to further transform perioperative pain management.Have you struggled with limited options for managing your patients' postoperative pain? Subscribe to the Anesthesia Patient Safety Podcast for more on groundbreaking developments like Suzetrigine that are changing how we approach patient care and safety. Leave us a review to share your thoughts on this revolutionary advance in pain management.For show notes & transcript, visit our episode page at apsf.org: https://www.apsf.org/podcast/265-the-breakthrough-drug-changing-perioperative-pain-management/© 2025, The Anesthesia Patient Safety Foundation

Dr. Keya Locke interviews Drs. Barbara Rogers and Shobana Rajan, guest editors of the August ASA Monitor, about preoperative medication management. Listen in as they discuss the state of long-standing medication debates, consider new trends and medications, and share thoughts on why the role of anesthesiologists as pre-op physicians is increasing in importance. Recorded July 2025.

Is it time to rethink perioperative immunotherapy in resectable gastric and gastroesophageal junction (GEJ) cancers? See the latest data and expert takeaways.   Credit available for this activity expires: 7/18/2026 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1002710?ecd=bdc_podcast_libsyn_mscpedu

Did you know that immunotherapy has shown promise in the perioperative setting for gastric and gastroesophageal junction (GEJ) adenocarcinoma? Credit available for this activity expires: 7/11/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/transforming-gastric-and-gej-cancer-care-perioperative-2025a1000i7e?ecd=bdc_podcast_libsyn_mscpedu

The final instalment of our series “Perioperative Pain Management” is a panel discussion where we answer the question: What are the various challenges and strategies in managing perioperative pain, particularly with regard to opioid use? The discussion covers the complexities of opioid de-escalation in preoperative periods, the benefits and risks of opioid-free anesthesia, and the use of multimodal approaches. We also touch on the coordination of patient care across multiple specialties and the impact of intraoperative practices on postoperative pain management and long-term opioid use. The session emphasizes the importance of patient education, consistent communication, and empowered collaboration among healthcare providers. The speakers on the panel are; Tim Miller, Professor of Anesthesiology at Duke University Medical Center, Fauzia Hasnie, Consultant Lead, Opioid Multidisciplinary Pain Management Clinic, Joint Lead, Combined Sickle-Opioid Virtual Multidisciplinary Clinic Guy's & St Thomas' NHS Foundation Trust, and Esteban Salas Rezola, Specialist in Anaesthesiology, Resuscitation and Pain Therapy at Hospital General Alicante. Chaired by John Whittle, Clinical Academic working in Perioperative Translational Medicine at UCL and Honorary Consultant in Perioperative Medicine, Anaesthesia and Critical Care at University College Hospitals London. The three presentations which accompany this piece are here: https://topmedtalk.libsyn.com/perioperative-pain-management-the-opioid-epidemic-and-opioid-reduction-strategies https://topmedtalk.libsyn.com/perioperative-pain-management-opioid-reduction-service https://topmedtalk.libsyn.com/perioperative-pain-management-opioid-sparing-analgesia-strategies-guided-by-nol-index

Staffing shortages and burnout have left many ORs struggling to stay efficient — but what if there was a simple solution that gave you time back while also protecting your sterile field? In today's First Case Vendor Spotlight™, we're going to learn all about this time and staff saving solution with Laurel Stebbins, Clinical Manager, and Alex Navlet, Clinical Consultant, with TIDI Products, along with Maria Candelaria, a perioperative nurse and current user of the Sterile-Z® drape. The Sterile-Z® is a game-changing drape that helps surgical teams stay efficient, compliant, and stress-free. In this discussion, we'll hear firsthand how this clear, easy-to-use drape improves workflow, reduces contamination risk, and even helps teams take a much-needed break — without compromising sterility. The Sterile-Z® line now includes options for Mayo stands and 3D imaging procedures, all designed to save time, reduce waste, and protect your setup from airborne contamination. To learn more or request a sample, visit tidiproducts.com/sterile-z and follow them on LinkedIn, Facebook, Instagram, and TikTok! #operatingroom #sterilefield #surgicalefficiency #ORNurse #scrubtech #perioperative #vendorspotlight #podcast #SterileZ

This series of talks hits upon one of the longstanding themes of TopMedTalk, opioids and opioid reduction in a perioperative setting. We discuss the opioid epidemic, the issue of persistent opioid use after surgery, and strategies for opioid reduction. Topics include historical usage, the dangers of high-dose opioids, and alternative pain management techniques such as opioid-free anesthesia and multimodal analgesia. The discussion also highlights the importance of ongoing research, patient education, and evidence-based practices to minimize the side effects of opioids while ensuring effective pain management. Presented by Tim Miller, Professor of Anesthesiology at Duke University Medical Center. Tim completed his training in Nottingham, UK followed by a fellowship in cardiothoracic anaesthesia at Glenfield Hospital, Leicester, UK. He is a fellow of the Royal College of Anaesthetists.

In this piece we look at the opioid crisis in the UK and how it has translated into clinical practice. Hear about the history and data behind opioid prescription trends, specifically highlighting the high-risk patient demographics and mortality figures associated with opioid use. Learn how a multidisciplinary approach, taken by the opioid reduction service at Guy's & St. Thomas', helps showcase early outcome data and the strategies employed in opioid weaning. Emphasizing the importance of patient engagement and personalized care we detail the clinic's processes, preparations, and long-term strategies for opioid tapering. The episode concludes with a compelling patient testimonial video reflecting the positive outcomes of the service. Fauzia Hasnie, Consultant Lead, Opioid Multidisciplinary Pain Management Clinic, Joint Lead, Combined Sickle-Opioid Virtual Multidisciplinary Clinic Guy's & St Thomas' NHS Foundation Trust. Resources: UK National Institute for Health Care Excellence (NICE) guidelines: Overview | Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adults | Guidance | NICE US Centers for Disease Control and Prevention (CDC): Guideline Recommendations and Guiding Principles | Overdose Prevention | CDC

In this 311th episode I welcome Dr. Mark Nelson to the show to discuss his management aid that helps clinicians easily figure out how to handle all types of AICDs and Pacers in the perioperative period. Our Sponsors:* Check out Eko: https://ekohealth.com/ACCRAC* Check out FIGS and use my code FIGSRX for a great deal: https://wearfigs.com* Check out Factor: https://factormeals.com/accrac50offAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

Dr. Mike Guertin, Professor of Anesthesiology and Chief Perioperative Medical Director at Ohio State University Wexner Medical Center, joins the podcast to reflect on the evolution of his career and the leadership lessons he's gained along the way. He discusses his experience in an MBA program and how it has shaped his approach to healthcare leadership. Dr. Guertin also sheds light on the ongoing anesthesia shortage and its implications for care delivery.

This piece focuses on strategies for opioid-sparing anesthesia guided by the NOL Index, emphasizing the variability in patient responses to opioids. The importance of monitoring nociception, using advanced devices and techniques to customize opioid dosing, reduce side effects, and confirm the effectiveness of regional anesthesia. Our presenter shares personal experiences from their professional life and case studies, illustrating the benefits and challenges of implementing multimodal and opioid-free anesthesia approaches. The talk highlights the need for individualized treatment strategies in critical care and anesthesia. Presented by Esteban Salas Rezola, Specialist in Anaesthesiology, Resuscitation and Pain Therapy at Hospital General Alicante.

July 2025 Journal Club Podcast Title: Perioperative Glucagon-Like Peptide-1 Agonist Use and Rates of Pseudarthrosis After Single-Level Lumbar Fusion: A Large Retrospective Cohort Study To read journal article: https://journals.lww.com/neurosurgery/fulltext/2025/07000/perioperative_glucagon_like_peptide_1_agonist_use.9.aspx Author: Konstantinos Margetis Guest Faculty: Stephen Kalhorn Moderator: Brian Saway Committee Co-Chair: Kimberly Hoang

Maintaining the sterility of surgical instruments is paramount to preventing infections and ensuring patient safety. AORN's updated guideline on packaging for sterilization provides crucial guidance for perioperative teams, addressing key concerns and promoting best practices for selecting, using, and maintaining packaging systems.Addressing Critical Issues in Packaging for SterilizationAORN periodically reviews and updates its guidelines to reflect current evidence and best practices. This update focuses on several critical areas:Packaging Defects: The guideline emphasizes the importance of minimizing packaging defects that can compromise sterility. Personnel Discomfort:Recognizing the ergonomic challenges faced by sterile processing professionals, the guideline addresses strategies to create a more comfortable and safe work environment.Quality of Pouches and Wraps: The guideline stresses the importance of inspecting single-use wraps and filters for defects before use.Streamlining Instrument Sets: The guideline encourages optimizing instrument sets to eliminate unnecessary instruments, streamlining processes, and potentially saving time and resources.Packaging for Sterilization Guideline Changes and Enhancements:Ergonomic Considerations: The guideline emphasizes creating an ergonomic work environment for sterile processing professionals, including comfortable work surface heights, adjustable seating, adequate space for assembling trays, proper lighting, noise reduction, and anti-fatigue mats.Inspection of Wraps and Filters: The guideline reinforces the importance of inspecting all single-use wraps and filters for defects before assembling instrument sets.Streamlining Instrument Sets: New recommendations encourage facilities to streamline instrument sets by identifying and removing infrequently used instruments. This can improve efficiency and reduce costs.Pouch Use and Technique: The guideline provides detailed recommendations for using peel pouches (paper/plastic), including proper sizing, sealing techniques, and inspection of seals for gaps, folds, bubbles, or wrinkles.Heat Sealer Maintenance: The guideline emphasizes the importance of using heat sealers according to the manufacturer's instructions, ensuring correct temperature settings for different materials, and maintaining equipment for optimal performance.Support the showWelcome to the Periop Talk—your go-to vlog and podcast series where we examine the world of perioperative nursing.Episode after episode, we're bringing you professional tips, clinical wisdom, and personal stories that'll make you feel like you're chatting with your work BFFs. Curious about the latest surgical techniques? We got you. Wondering how to navigate the challenges of the periop journey? We're here for that too.Our vlog and podcast series isn't just about sharing information; it's about building a community. Meet the people behind the masks, hear their journeys, and join the rotation of periop professionals making a difference. From students and new nurses to seasoned pros, we've got content for every stage of your perioperative practice.Periop Talk is your peek behind the red line to the world of perioperative nursing. It's not just about the OR – it's about the heart and soul of healthcare. Let's scrub in and share the periop love!Watch us at: (1) Periop Talk vlog - YouTube

Sodium-glucose cotransporter-2 (SGLT2) inhibitors have revolutionized treatment for type 2 diabetes, heart failure, and chronic kidney disease—but they're creating new challenges for anesthesia professionals. With more patients on these medications heading to surgery, understanding their unique perioperative risks has never been more critical.At the heart of this issue lies euglycemic ketoacidosis—a potentially life-threatening complication that's particularly insidious because it lacks the classic hyperglycemia that would normally trigger suspicion. We dive deep into the latest evidence, revealing that patients on SGLT2 inhibitors have an increased risk of developing postoperative ketoacidosis compared to those not taking these medications, with significantly worse outcomes when complications occur.We present a practical algorithm for risk stratification, considering factors like procedure duration, anesthesia type, diabetes control, and comorbidities. You'll learn which patients should hold their medication, which can proceed with caution, and what monitoring strategies to implement when patients haven't properly discontinued their medication before surgery. This guidance is especially valuable for emergency cases where postponement isn't an option.Whether you're developing institutional protocols or making decisions for individual patients, this episode equips you with the knowledge to navigate the complexities of SGLT2 inhibitor management in the perioperative period. Subscribe to stay informed about the latest in anesthesia patient safety and join our mission to ensure no one is harmed by anesthesia care.For show notes & transcript, visit our episode page at apsf.org: https://www.apsf.org/podcast/257-sweet-trouble-perioperative-management-of-sglt2-inhibitors/© 2025, The Anesthesia Patient Safety Foundation

In today's episode, we spoke with Matthew Galsky, MD, about the FDA approval of neoadjuvant durvalumab (Imfinzi) plus gemcitabine and cisplatin followed by adjuvant durvalumab monotherapy after radical cystectomy for the treatment of adult patients with muscle-invasive bladder cancer (MIBC). Dr Galsky is a professor of medicine (hematology and medical oncology), a professor of urology, director of Genitourinary Medical Oncology, co-director of the Center of Excellence for Bladder Cancer, and director for Translational Research at The Tisch Cancer Institute in New York, New York. In our exclusive interview, Dr Galsky discussed the significance of this approval, key efficacy and safety data from the pivotal phase 3 NIAGARA trial (NCT03732677), and the role of this regimen in the MIBC treatment paradigm, including for cisplatin-eligible patients with mild renal impairment.

In today's episode of Value-Based Care Insights, host Daniel J. Marino sits down with Dr. Amit Jain, MD, MBA, Associate Professor of Orthopedic Surgery and Neurosurgery, Chief of Minimally Invasive Spine Surgery at Johns Hopkins, and Director of Value-Based Care for Johns Hopkins Health System. Together, they unpack how organizations can reduce costs while improving performance outcomes such as length of stay and readmission rates—ultimately advancing their value-based care strategy. Explore expert insights on aligning surgical services with cost-effective, high-quality care delivery.

On this episode Lara and Vyanka talk to Dr Louise Savic from Leeds Teaching Hospitals NHS Trust all about diagnosis and testing for perioperative anaphylaxis. This is ImmunoTea: Your Immunology Podcast, presented by Dr Lara Dungan and Dr Vyanka Redenbaugh. This is the show where we tell you all about the most exciting research going on in the world of immunology. So grab a cup of tea, sit down and relax and we'll fill you in. Contact us at ImmunoTeaPodcast@gmail.com or @ImmunoTea on twitter. Hosted on Acast. See acast.com/privacy for more information.

Ep 127 - Dr. Jain- Improving Perioperative Services to Enhance Value-Based Care Exploring one of the most significant drivers of total cost of care: surgical and perioperative services. With surgical services accounting for up to 70% of a hospital's revenue, inefficiencies in the OR can have a profound impact on both financial and clinical outcomes. On this episode Dan sits down with Dr. Amit Jain, Associate Professor of Orthopedic Surgery and Neurosurgery and Chief of Minimally Invasive Spine Surgery at Johns Hopkins. Dr. Jain also serves as Director of Value-Based Care for Johns Hopkins Health System. Together, they unpack how organizations can reduce costs while improving performance outcomes such as length of stay and readmission rates—ultimately advancing their value-based care strategy. Tune in for expert insights on aligning surgical services with cost-effective, high-quality care delivery. To stream our Station live 24/7 visit www.HealthcareNOWRadio.com or ask your Smart Device to “….Play Healthcare NOW Radio”. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

Welcome to another episode of the Oncology Brothers podcast! In this episode, we dived into the recent FDA approval of Durvalumab combined with chemotherapy for resectable muscle-invasive bladder cancer, based on the NIAGARA trial. Join us as we chat with Dr. Thomas Powles, a GU medical oncologist and the lead author of the NIAGARA trial. We discussed the study design, the significant improvements in overall survival, and the implications of this new treatment approach. Dr. Powles shared insights on the use of immunotherapy in the perioperative setting, the importance of pathological complete response, and the safety of combining Durvalumab with chemotherapy. Key topics covered in this episode: •⁠  ⁠Overview of the NIAGARA trial and its findings •⁠  ⁠Comparison of Durvalumab and cisplatin-based chemotherapy outcomes •⁠  ⁠The significance of event-free survival and overall survival rates •⁠  ⁠Insights on managing side effects and treatment sequencing •⁠  ⁠The evolving role of ctDNA in determining treatment strategies YouTube: https://youtu.be/s_tXoX5yhV8 Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Tune in to learn how these advancements are changing the landscape of bladder cancer treatment and improving patient outcomes. Don't forget to like, subscribe, and check out our other episodes for more insights on oncology and FDA approvals! #OncologyBrothers #BladderCancer #Dervalumab #FDAApproval #NiagaraTrial #Immunotherapy #CancerResearch #OncologyPodcast

Have you ever wondered about the potential impact of surgery and anesthesia on cognitive function? Today's show will discuss the complexities of Perioperative Neurocognitive Disorders (PND), a term encompassing conditions like postoperative delirium (POD), postoperative cognitive decline (POCD), and delayed neurocognitive recovery (DNR). Through insightful discussions rooted in the latest research, we aim to shed light on: The prevalence and impact of PND, drawing from studies highlighting its occurrence after various surgical procedures. Potential risk factors that may make individuals more susceptible to developing PND. Innovative approaches for prevention and management, including the investigation of medications like dexmedetomidine and anesthetic techniques such as total intravenous anesthesia (TIVA) with propofol, which some studies suggest may have neuroprotective properties. The intricate underlying mechanisms of PND, exploring the roles of neuroinflammation, oxidative stress, and even insulin signaling in the central nervous system. The use of monitoring techniques like electroencephalography (EEG) to better understand and potentially mitigate neurocognitive complications. The importance of early identification and comprehensive care for individuals experiencing PND. Visit us online: https://beyondthemaskpodcast.com/ The 1099 CRNA Institute: https://aana.com/1099 Get the CE Certificate here (and directly submit to the NBCRNA): https://beyondthemaskpodcast.com/wp-content/uploads/2020/04/Beyond-the-Mask-CE-Cert-FILLABLE.pdf Help us grow by leaving a review: https://podcasts.apple.com/us/podcast/beyond-the-mask-innovation-opportunities-for-crnas/id1440309246 Donate to Our Heart Your Hands here: https://www.ourheartsyourhands.org/donate  Support Team Emma Kate: https://grouprev.com/haloswalk2024-shannon-shannon-brekken

Listen as we discuss the highly-awaited ESOPEC trial, which examines treatment regimens for esophageal and EGJ adenocarcinoma. Wildly impress your thoracic attendings or peers with your nuanced knowledge! FLOT who? You'll know. Pull out the paper and listen along! Learning Objectives: -Discuss the patient population in the ESOPEC trial -Discuss the main differences between the ESOPEC trial and the CROSS trial -Describe the main drawbacks between FLOT and the CROSS regimen. Hosts: Chloe Hanson MD, Brian Louie MD, and Peter White MD   Referenced Material https://www.nejm.org/doi/full/10.1056/NEJMoa2409408 Hoeppner J, Brunner T, Schmoor C, Bronsert P, Kulemann B, Claus R, Utzolino S, Izbicki JR, Gockel I, Gerdes B, Ghadimi M, Reichert B, Lock JF, Bruns C, Reitsamer E, Schmeding M, Benedix F, Keck T, Folprecht G, Thuss-Patience P, Neumann UP, Pascher A, Imhof D, Daum S, Strieder T, Krautz C, Zimmermann S, Werner J, Mahlberg R, Illerhaus G, Grimminger P, Lordick F. Perioperative Chemotherapy or Preoperative Chemoradiotherapy in Esophageal Cancer. N Engl J Med. 2025 Jan 23;392(4):323-335. doi: 10.1056/NEJMoa2409408. PMID: 39842010. https://www.nejm.org/doi/full/10.1056/NEJMoa1112088 van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, Richel DJ, Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, Cuesta MA, Blaisse RJ, Busch OR, ten Kate FJ, Creemers GJ, Punt CJ, Plukker JT, Verheul HM, Spillenaar Bilgen EJ, van Dekken H, van der Sangen MJ, Rozema T, Biermann K, Beukema JC, Piet AH, van Rij CM, Reinders JG, Tilanus HW, van der Gaast A; CROSS Group. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012 May 31;366(22):2074-84. doi: 10.1056/NEJMoa1112088. PMID: 22646630. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)32557-1/abstract Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, Kopp HG, Mayer F, Haag GM, Luley K, Lindig U, Schmiegel W, Pohl M, Stoehlmacher J, Folprecht G, Probst S, Prasnikar N, Fischbach W, Mahlberg R, Trojan J, Koenigsmann M, Martens UM, Thuss-Patience P, Egger M, Block A, Heinemann V, Illerhaus G, Moehler M, Schenk M, Kullmann F, Behringer DM, Heike M, Pink D, Teschendorf C, Löhr C, Bernhard H, Schuch G, Rethwisch V, von Weikersthal LF, Hartmann JT, Kneba M, Daum S, Schulmann K, Weniger J, Belle S, Gaiser T, Oduncu FS, Güntner M, Hozaeel W, Reichart A, Jäger E, Kraus T, Mönig S, Bechstein WO, Schuler M, Schmalenberg H, Hofheinz RD; FLOT4-AIO Investigators. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019 May 11;393(10184):1948-1957. doi: 10.1016/S0140-6736(18)32557-1. Epub 2019 Apr 11. PMID: 30982686. ***Fellowship Application Link: https://forms.gle/PQgAvGjHrYUqAqTJ9 Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more. If you liked this episode, check out our recent episodes here: https://app.behindtheknife.org/listen

In this episode, Dr. Sergion Zanotti discusses TEE in cardiac arrest and shock. Critical care clinicians commonly utilize transthoracic echocardiography in the ICU as part of their point-of-care-ultrasonography (POCUS) toolkit. However, there is a growing push to train intensivists in using transesophageal echocardiography (TEE) for cardiac arrest and peri-arrest situations in the ICU. Our guest is Dr. Sara Nikravan, a cardiothoracic anesthesia critical care physician with training in advanced perioperative echocardiography. Dr. Nikravan is an Associate Professor of Cardiothoracic Anesthesiology and Critical Care Medicine at the University of Washington Medical School and practices at the UW Medical Center. She is recognized as an expert and master educator in Critical Care, Perioperative echocardiography, and Point of Care Ultrasound. She has authored numerous peer-reviewed papers and is the guidelines co-chair of the Society of Critical Care Medicine Guidelines on Adult Critical Care Ultrasonography: Focused Update 2024, recently published in Critical Care Medicine.  Additional links: Society of Critical Care Medicine Guidelines on Adult Critical Care Ultrasonography: Focused Update 2024, Crit Care Med 2025: https://pubmed.ncbi.nlm.nih.gov/39982182/ Focused Transesophageal Echocardiography During Cardiac Arrest Resuscitation: JACC Review Topic of the Week. JACC 2020: https://pubmed.ncbi.nlm.nih.gov/32762909/ Landing page for the Resuscitative TEE Project website: https://www.resuscitativetee.com/ Books mentioned in this episode: The Prophet. By Kahlil Gibran: https://www.amazon.com/dp/998247037X?psc=1&smid=ATVPDKIKX0DER&ref_=chk_typ_imgToDp

This week, we discuss another set of high yield topic for anyone who cares for patients on anticoagulation - how to safely hold anticoagulation prior to a procedure and how to reverse the effects of the drug in the even of an emergent situation. We discuss our approach to how we discuss this with our patients and our medical colleagues! Dan also shares his dotphrases for your reference! Episode contents:- How do we approach peri-operative anticoagulation management? When do we hold? How long do we hold? Do they need bridging? No bridging? - In the case of a severe bleed, how do we reverse the effects of anticoagulation?**** Get paid to participate in market research surveys: https://affiliatepanel.members-only.online/FOC_24?utm_campaign=FOC&utm_source=email&utm_medium=email** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodesLove what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast

Sharpen your approach to high-risk renal cell carcinoma (RCC). In this episode of BackTable Urology, guest Dr. Sumanta (Monty) Pal from City of Hope joins host Dr. Aditya Bagrodia to discuss contemporary kidney cancer treatment and the complexities of perioperative therapy. --- This podcast is supported by: Photocure https://www.photocure.com/ --- SYNPOSIS The conversation covers the challenging side effects of perioperative treatments, the evolution of therapies from tyrosine kinase inhibitors to modern checkpoint inhibitors, and the introduction of adjuvant therapies. Dr. Pal and Dr. Bagrodia explore the impact of these treatments on patient outcomes, the challenges with current biomarkers, and the potential of emerging trials. The doctors also highlight the importance of personalized RCC management strategies, particularly for high-risk patients and non-clear cell histologies. They also emphasize the need for appropriate patient counseling in this emerging field. --- TIMESTAMPS 00:00 - Introduction 01:53 - Evolution of Kidney Cancer Treatments 03:30 - Tyrosine Kinase Inhibitors in the 2010s 10:42 - Checkpoint Inhibitor Trials 23:09 - Discussing Adjuvant Therapy with Patients 26:56 - Restaging and Biomarkers 31:58 - Challenges in Adjuvant Immunotherapy 39:57 - Non-Clear Cell RCC 41:42 - Future Directions --- RESOURCES Photocure: https://www.photocure.com/

2024 ACC/AHA guideline update, including biomarker testing, MINS, and other consulting tips Master perioperative medicine! Learn when to hold ACE inhibitors, how to manage OSA without delaying surgery, and why "NPO after midnight" is outdated. We're joined by Dr. Avital O'Glasser, our Chief of Perioperative Medicine! Claim CME for this episode at curbsiders.vcuhealth.org! Patreon | Episodes | Subscribe | Spotify | YouTube | Newsletter | Contact | Swag! | CME Show Segments Intro Case Preoperative Assessment & Consulting Tips Risk Calculators Frailty Pulmonary Considerations Cardiovascular Meds & BP Management NPO: Why Are We Still Doing This? Biomarkers & Postoperative Risk MINS Outro Credits Written and produced, show notes, cover art, CME, and infographics: Paul Wurtz MD.  Hosts: Matthew Watto MD, FACP; Paul Williams MD, FACP Reviewer: Molly Heublein MD Showrunners: Matthew Watto MD, FACP; Paul Williams MD, FACP Technical Production: PodPaste Guest: Avital O'Glasser MD Disclosures Dr. O'Glasser reports no relevant financial disclosures. The Curbsiders report no relevant financial disclosures.  Sponsor: EZResus  Listeners of the Cribsiders and Curbsiders podcasts get access to a 2-month free trial,letting them use 100% of the features of the  For more information, www.ezresus.com/curbsiders and Use promo code Curbsiders Sponsor: Freed Visit Freed.ai and Usecode:CURB50 to get $50 off your first month when you subscribe. Sponsor: Mint Mobile Get 3 months of premium wireless service from Mint Mobile for $15 a month.Shop plans at mintmobile.com/curb